Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06556810 · ClinicalTrials.gov registry record · Phase 1
IC14 for Treatment of Acute Decompensated Heart Failure
A Phase 1 study of Acute Decompensated Heart Failure, sponsored by Implicit Bioscience.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06556810: Active Phase 1 study of Acute Decompensated Heart Failure, sponsored by Implicit Bioscience.
NCT06556810 is a Phase 1 study of Acute Decompensated Heart Failure that is active but no longer recruiting, run by Implicit Bioscience. The registered enrollment target is 10 participants, below the 458-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06556810, a Phase 1 study of Acute Decompensated Heart Failure, is active but no longer recruiting, sponsored by Implicit Bioscience.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14. The main questions it aims to answer are: Is the drug IC14 safe in patients with ADHF? What are the IC14 drug levels in the bloodstream after treatment with IC14? What is the impact of IC14 treatment on markers of disease in the bloodstream? What is the impact of IC14 treatment on measures of heart failure? There is no placebo arm in this study. Participants will: Take drug IC14 once via an intravenous infusion After the infusion, be visited in the hospital or visit the clinic 5 times for checkups and tests Answer questions about their medical status via a phone call 3 months after the infusion
Primary Outcome
safety measured by treatment-emergent adverse events, including abnormal laboratory values
Conditions Studied
Interventions
- DRUG Atibuclimab (IC14)
Study Locations (2)
Virginia
- University of Virginia - Charlottesville
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 1 |
What the registry record for NCT06556810 still lists
NCT06556810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 458-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Acute Decompensated Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Atibuclimab (IC14) is the first listed.
NCT06556810 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06556810 about?
NCT06556810 is a clinical study titled "IC14 for Treatment of Acute Decompensated Heart Failure". The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14. The main questions it aims to answer are: Is the drug IC14 safe in patients with ADHF? What are the I...
What is the current status of trial NCT06556810?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-10-17. Estimated completion is 2026-01-31.
What conditions does trial NCT06556810 study?
This clinical trial studies the following conditions: Acute Decompensated Heart Failure.
What interventions are being tested in trial NCT06556810?
The interventions under investigation include: Atibuclimab (IC14) (DRUG).
Who is sponsoring clinical trial NCT06556810?
This trial is sponsored by Implicit Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06556810 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Decompensated Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06556810's enrollment target sits among peer trials
10 11th of 12 higher than 1 of 12 other Acute Decompensated Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Decompensated Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
RECRUITING · Phase 3
-
Low Level Tragus Stimulation in Acute Decompensated Heart Failure
RECRUITING · NA
-
Change in Stroke Volume Index After Diuresis for Patients With Decompensated Heart Failure
RECRUITING
-
DORAYA-HF Early Feasibility Study
ACTIVE NOT RECRUITING · NA
-
Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI